These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1664825)

  • 21. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections.
    Stein GE; Havlichek DH
    Pharmacotherapy; 1997; 17(6):1139-47. PubMed ID: 9399598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin.
    Azoulay-Dupuis E; Bedos JP; Vallée E; Pocidalo JJ
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():45-53. PubMed ID: 1664829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
    Thys JP; Jacobs F; Byl B
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):304-15. PubMed ID: 1864291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of temafloxacin on the pharmacokinetics of theophylline.
    Ruff F; Santais MC; Callens E; Chauvin JP; Hazebroucq J
    Am J Med; 1991 Dec; 91(6A):76S-80S. PubMed ID: 1662899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind randomized study of oral temafloxacin and cefadroxil in patients with mild to moderately severe bacterial skin infections.
    Neldner KH
    Am J Med; 1991 Dec; 91(6A):111S-114S. PubMed ID: 1662879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temafloxacin vs ciprofloxacin for UTI.
    Ganiats TG; Norcross WA
    J Fam Pract; 1992 Jul; 35(1):14, 16, 18. PubMed ID: 1319461
    [No Abstract]   [Full Text] [Related]  

  • 30. Penetration of temafloxacin into body tissues and fluids.
    Sörgel F
    Clin Pharmacokinet; 1992; 22 Suppl 1():57-63. PubMed ID: 1319872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
    Arai S; Gohara Y; Akashi A; Kuwano K; Nishimoto M; Yano T; Oizumi K; Takeda K; Yamaguchi T
    Antimicrob Agents Chemother; 1993 Feb; 37(2):287-92. PubMed ID: 8383942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temafloxacin vs ciprofloxacin for UTI.
    Hornstein LE
    J Fam Pract; 1992 Jul; 35(1):14; author reply 18. PubMed ID: 1319460
    [No Abstract]   [Full Text] [Related]  

  • 33. An assessment of temafloxacin in the treatment of chronic bacterial prostatitis.
    Naber KG; Boerema JB; Bischoff W; Blenk H; Focht J; Carpentier P; Sylvester J
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():87-96. PubMed ID: 1664834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.
    Sorgel F; Naber KG; Kinzig M; Mahr G; Muth P
    Am J Med; 1991 Dec; 91(6A):51S-66S. PubMed ID: 1662896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of antacid medication on the pharmacokinetics of temafloxacin.
    Granneman GR; Stephan U; Birner B; Sörgel F; Mukherjee D
    Clin Pharmacokinet; 1992; 22 Suppl 1():83-9. PubMed ID: 1319875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of experience with ofloxacin in respiratory tract infection.
    Ball P
    Scand J Infect Dis Suppl; 1990; 68():56-63. PubMed ID: 2218424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the pharmacokinetic profile of temafloxacin.
    Dudley MN
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():55-64. PubMed ID: 1664830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temafloxacin: in vitro comparison with five other antibacterial agents.
    Digranes A; Hardardottir H; Bottolfsen KL
    Chemotherapy; 1991; 37(2):98-105. PubMed ID: 2032475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.